Nintedanib clinical trials
Also written BIBF 1120, Vargatef, Ofev® and Intedanib.
How each study uses nintedanib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nintedanib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 15 Oct 2014 · OFEV · NDA 205832 (FDA, Drugs@FDA)
- European Union
- 21 Nov 2014 · Vargatef · EMEA/H/C/002569 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
140 studies that test it; most in 2015 (14); 1 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 7 |
| 2006 | 5 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 8 |
| 2010 | 2 |
| 2011 | 9 |
| 2012 | 6 |
| 2013 | 7 |
| 2014 | 12 |
| 2015 | 14 |
| 2016 | 12 |
| 2017 | 7 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 7 |
| 2021 | 10 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 74 · Other 67
Boehringer Ingelheim (61) · Roswell Park Cancer Institute (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Assistance Publique - Hôpitaux de Paris (3) · Sunshine Lake Pharma Co., Ltd. (2) · Hospices Civils de Lyon (2) · Memorial Sloan Kettering Cancer Center (2) · M.D. Anderson Cancer Center (2)
Often tested with
Tested in the same studies.
Pirfenidone (11) · Afatinib (5) · Docetaxel (4) · Yinfenidone (2) · Tocilizumab (2) · Nivolumab (1) · Azacitidine (1) · Nerandomilast (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test nintedanib.
- Dec 2026Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) PatientsPhase 2 · Dr. Romain Lazor
- Mar 2027Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)Phase 2 · First Affiliated Hospital of Wenzhou Medical University
Studies
Open first, then newest update. How each study uses nintedanib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 141
- A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisNot yet recruitingPhase 3Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07335562Written as Nintedanib
- Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)Not yet recruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07583589Written as Nintedanib,Dextromethorphan
- Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung DiseaseRecruitingPhase 3National Institute of Geriatrics, Rheumatology and Rehabilitation, PolandNCT06297096Written as Nintedanib
- A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung CancerNot yet recruitingPhase 4The Affiliated Hospital of Qingdao UniversityNCT07485920Written as Tislelizumab and nintedanib
- Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) PatientsRecruitingPhase 2Dr. Romain LazorNCT04976036Written as Nintedanib
- Nintedanib for Improving Reproductive Outcomes in AdenomyosisNot yet recruitingPhase 3Sun Yat-sen UniversityNCT07162961Written as Nintedanib
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingPhase 1/2China Medical University HospitalNCT06071013Written as Nintedanib, gefitinib, erlotinib, afatinib, osimertinib
- RCT of Nintedanib in Fibrotic SarcoidosisRecruitingPhase 4Post Graduate Institute of Medical Education and Research, ChandigarhNCT06479603Written as Nintedanib
- Nintedanib Treatment in Unicentric Castleman DiseaseNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06643091Written as Nintedanib
- Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary FibrosisRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT04541680Written as Nintedanib 150 MG [Ofev]
- The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19CompletedPhase 4Icahn School of Medicine at Mount SinaiNCT04619680Written as Nintedanib
- Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell TransplantationCompletedPhase 2University Hospital, Basel, SwitzerlandNCT03805477Written as Nintedanib
- Myositis Interstitial Lung Disease Nintedanib TrialCompletedPhase 4Rohit Aggarwal, MDNCT05799755Written as Nintedanib
- Phase II Study of Docetaxel +/- Nintedanib in Breast CancerCompletedPhase 2Centre Oscar LambretNCT01658462Written as Nintedanib
- Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and NintedanibCompletedPhase 1PureTechNCT06717100Written as Nintedanib 150 MG [Ofev]
- Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy SubjectsCompletedPhase 1Sunshine Lake Pharma Co., Ltd.NCT07588646Written as Nintedanib
- Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerActive, not recruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT03377023Written as Nintedanib
- A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)CompletedPhase 3Boehringer IngelheimNCT05285982Written as Nintedanib (Ofev®)
- Management of Progressive Disease in Idiopathic Pulmonary FibrosisCompletedPhase 4Hospices Civils de LyonNCT03939520Written as pirfenidone and nintedanib
- Trial Of Pembrolizumab And NintedanibCompletedPhase 1Gustave Roussy, Cancer Campus, Grand ParisNCT02856425Written as Nintedanib
See all 141 studies that test nintedanib →
Given beside what is tested · 7 — nintedanib is usual care or a partner of the new treatment
- A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy ParticipantsRecruitingPhase 1Endeavor Biomedicines, Inc.NCT07454291Written as nintedanib
- A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on NintedanibCompletedPhase 1GlaxoSmithKlineNCT06625489Written as Nintedanib
- A Study in Healthy Men to Find the Best Formulation for Once Daily Intake of NintedanibCompletedPhase 1Boehringer IngelheimNCT05262751Written as Ofev®
- Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)TerminatedPhase 4Boehringer IngelheimNCT03717012Written as Nintedanib
- Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function ImpairmentCompletedPhase 3Boehringer IngelheimNCT02802345Written as Nintedanib
- BIBF 1120 Versus Bevacizumab in Metastatic Colorectal CancerCompletedPhase 2Boehringer IngelheimNCT00904839Written as BIBF 1120
- A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung CancerCompletedPhase 1Boehringer IngelheimNCT02182232Written as BIBF 1120
As the comparator · 1 — what is tested is compared with nintedanib
Codes
What other systems call nintedanib · ClinicalTrials.gg INT005300
- MeSH (NLM) C530716nintedanibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G6HRD2P839NINTEDANIBConfirmed FDA, NLM, Wikidata
- RxNorm 1592737Confirmed FDA, Wikidata
- Wikidata Q15149723nintedanibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62765NintedanibOne source FDA
- DrugBank DB09079One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C530716 | nintedanib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G6HRD2P839 | NINTEDANIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1592737 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15149723 | nintedanib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62765 | Nintedanib | One source FDA |
| DrugBank | DB09079 | — | One source Wikidata |
Also registered as nintedanib esylate (UNII 42F62RTZ4G · RxNorm 1592736).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.